Pivotal phase III trial of RP 5063 in patients with schizophrenia.
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2013
Price : $35 *
At a glance
- Drugs Brilaroxazine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Reviva Pharmaceuticals
- 06 Nov 2013 Study title is not official. MR 9155878 refers to multiple pivotal phase III trials, but there is no way of distinguishing them. Disease assumed.
- 06 Nov 2013 New trial record
- 05 Nov 2013 Initiation of pivotal phase III trials is planned for early 2014, according to a Reviva Pharmaceuticals media release. The company has received guidance from the FDA for the phase III development plan of RP 5063.